Market Cap 146.63B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 8.08
Forward PE 8.20
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 96,507,600
Avg Vol 72,390,898
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 45%
Beta 0.54
Analysts Sell
Price Target $28.41

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
LiquidThetaOptions
LiquidThetaOptions Nov. 15 at 10:00 AM
💎 LiquidTheta® Live Actionable Trade Asset: $PFE Contracts: $PFE December 18, 2026 $27 Calls Scale in: $1.75- $2.15 Scale out: $6.83-$11.70 Profit Potential : 154% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Alder77
Alder77 Nov. 15 at 9:00 AM
$ITRM $PFE Hostile takeover? Let's be serious, but who would do a hostile takeover of this shithole? For what, for 15 million a year? Pfizer makes 15mio in 20 or 30 seconds. Pfizer acquired a pharmaceutical company last week for 10 billion, and you think they're considering a hostile takeover of a company that's worth less than shit to them. Do you really believe the things you write? Our situation is dramatic, it's useless to find positives. Next year, 15 million in revenue, imagine how confident they are. For those who know Fishman and his way of speaking, you know very well that yesterday he was clearly communicating that it's over, he's failed. We'll probably be sold, but for really low prices. I'm starting to think that 100 million is already a success. Alternatives: bankruptcy, liquidation, and a gift to Pfizer.
0 · Reply
Paulzk
Paulzk Nov. 15 at 8:42 AM
$PFE The 171 million raised from the BNTX share sale is small potatoes. For PFE to lose 3.7 billion in market cap is way out of line. Perhaps a good buying entry point.
0 · Reply
Paulzk
Paulzk Nov. 15 at 8:26 AM
$PFE Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments. According to a regulatory filing, Pfizer reduced its ownership in the German firm by 54.7%, leaving it with about 1.66 million American Depositary Shares.
0 · Reply
Paulzk
Paulzk Nov. 15 at 8:24 AM
$PFE From Cramer article Pfizer’s very smart to buy Metsera in order to get a piece of the GLP-1 pie, even if it takes three years to be approved, and who knows how much time to scale the needed factories. But it could have another Lipitor on its hands. And even if this isn’t Lipitor part two, it’s definitely worth $10 billion to get into what may be the biggest class of drugs ever sold.”
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 7:59 AM
$PFE is currently trading at $25.06, with an RSI of 53.22 indicating neutral momentum. The 30-day moving average (MA30) is at $24.88, and the 50-day moving average (MA50) is at $24.79, suggesting a bullish trend as the price is above both MAs. The recent 60-day high of $27.69 provides a potential resistance level, while the low of $23.58 establishes a support zone. Directional bias is moderately bullish due to the price's position relative to the MAs and the RSI indicating no overbought conditions. Suggested entry is at $25.10, with a stop loss at $24.70 to protect against downside risk. Target 1 is set at $26.00, near the previous resistance, and Target 2 at $27.00, approaching the 60-day high. This plan leverages current price action and technical indicators for a calculated approach. https://privateprofiteers.com
0 · Reply
LamboSUV
LamboSUV Nov. 15 at 3:39 AM
$PFE can range between 25 and 27 as long as she wants. I will sell covered calls and collect the dividend. I love boring blue-chips.
2 · Reply
Twills08
Twills08 Nov. 15 at 3:01 AM
$ITRM $PFE I don’t disagree…the next two weeks are going to be interesting…
0 · Reply
QuantInsider
QuantInsider Nov. 15 at 1:45 AM
$PFE took a hit today with a 2.8% drop The biggest move was a massive ask-side sweep in Dec 19 $25 puts showing serious demand for downside protection That's 8,475 contracts at $670,849 This kind of action usually means traders expect more downside so be careful with fresh longs until things settle Plus, Reuters dropped news after the close that Starboard bailed on their PFE stake Losing that activist pressure could dampen any near-term upside Even with a 3% bounce over the last 5 days this combo makes the setup look pretty bearish right now
1 · Reply
Find_the_Cure
Find_the_Cure Nov. 15 at 1:42 AM
$PFE TRASH
0 · Reply
Latest News on PFE
Activist Starboard sells Pfizer stake after pushing for changes

Nov 14, 2025, 6:33 PM EST - 13 hours ago

Activist Starboard sells Pfizer stake after pushing for changes


Pfizer Completes Acquisition of Metsera

Nov 13, 2025, 11:26 AM EST - 1 day ago

Pfizer Completes Acquisition of Metsera

MTSR


BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 2 days ago

BioNTech says collaboration with Pfizer remains unchanged

BNTX


Pfizer to buy Metsera in deal worth up to $10 billion

Nov 10, 2025, 10:30 AM EST - 4 days ago

Pfizer to buy Metsera in deal worth up to $10 billion

MTSR


Dividend Income: Lanny's September 2025 Summary

Nov 10, 2025, 5:27 AM EST - 5 days ago

Dividend Income: Lanny's September 2025 Summary

O PEP PM TGT VYM VZ


Pfizer: The Storm Has Passed -- Tailwinds Ahead

Nov 6, 2025, 2:00 PM EST - 8 days ago

Pfizer: The Storm Has Passed -- Tailwinds Ahead


Pfizer's Slow Burn Comeback

Nov 6, 2025, 7:20 AM EST - 9 days ago

Pfizer's Slow Burn Comeback


Pfizer Responds to Delaware Chancery Court Ruling

Nov 5, 2025, 5:08 PM EST - 9 days ago

Pfizer Responds to Delaware Chancery Court Ruling


Pfizer: Market Still Pricing It At Crisis Valuations

Nov 5, 2025, 11:30 AM EST - 9 days ago

Pfizer: Market Still Pricing It At Crisis Valuations


Pfizer Inc. (PFE) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 3:56 PM EST - 10 days ago

Pfizer Inc. (PFE) Q3 2025 Earnings Call Transcript


Pfizer and Novo Nordisk both raise bids for Metsera

Nov 4, 2025, 12:18 PM EST - 10 days ago

Pfizer and Novo Nordisk both raise bids for Metsera

MTSR NVO


Dow Dips Over 400 Points; Pfizer Earnings Top Estimates

Nov 4, 2025, 9:53 AM EST - 10 days ago

Dow Dips Over 400 Points; Pfizer Earnings Top Estimates


Pfizer's Q3: Stagnation Continues

Nov 4, 2025, 9:26 AM EST - 10 days ago

Pfizer's Q3: Stagnation Continues


LiquidThetaOptions
LiquidThetaOptions Nov. 15 at 10:00 AM
💎 LiquidTheta® Live Actionable Trade Asset: $PFE Contracts: $PFE December 18, 2026 $27 Calls Scale in: $1.75- $2.15 Scale out: $6.83-$11.70 Profit Potential : 154% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Alder77
Alder77 Nov. 15 at 9:00 AM
$ITRM $PFE Hostile takeover? Let's be serious, but who would do a hostile takeover of this shithole? For what, for 15 million a year? Pfizer makes 15mio in 20 or 30 seconds. Pfizer acquired a pharmaceutical company last week for 10 billion, and you think they're considering a hostile takeover of a company that's worth less than shit to them. Do you really believe the things you write? Our situation is dramatic, it's useless to find positives. Next year, 15 million in revenue, imagine how confident they are. For those who know Fishman and his way of speaking, you know very well that yesterday he was clearly communicating that it's over, he's failed. We'll probably be sold, but for really low prices. I'm starting to think that 100 million is already a success. Alternatives: bankruptcy, liquidation, and a gift to Pfizer.
0 · Reply
Paulzk
Paulzk Nov. 15 at 8:42 AM
$PFE The 171 million raised from the BNTX share sale is small potatoes. For PFE to lose 3.7 billion in market cap is way out of line. Perhaps a good buying entry point.
0 · Reply
Paulzk
Paulzk Nov. 15 at 8:26 AM
$PFE Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments. According to a regulatory filing, Pfizer reduced its ownership in the German firm by 54.7%, leaving it with about 1.66 million American Depositary Shares.
0 · Reply
Paulzk
Paulzk Nov. 15 at 8:24 AM
$PFE From Cramer article Pfizer’s very smart to buy Metsera in order to get a piece of the GLP-1 pie, even if it takes three years to be approved, and who knows how much time to scale the needed factories. But it could have another Lipitor on its hands. And even if this isn’t Lipitor part two, it’s definitely worth $10 billion to get into what may be the biggest class of drugs ever sold.”
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 7:59 AM
$PFE is currently trading at $25.06, with an RSI of 53.22 indicating neutral momentum. The 30-day moving average (MA30) is at $24.88, and the 50-day moving average (MA50) is at $24.79, suggesting a bullish trend as the price is above both MAs. The recent 60-day high of $27.69 provides a potential resistance level, while the low of $23.58 establishes a support zone. Directional bias is moderately bullish due to the price's position relative to the MAs and the RSI indicating no overbought conditions. Suggested entry is at $25.10, with a stop loss at $24.70 to protect against downside risk. Target 1 is set at $26.00, near the previous resistance, and Target 2 at $27.00, approaching the 60-day high. This plan leverages current price action and technical indicators for a calculated approach. https://privateprofiteers.com
0 · Reply
LamboSUV
LamboSUV Nov. 15 at 3:39 AM
$PFE can range between 25 and 27 as long as she wants. I will sell covered calls and collect the dividend. I love boring blue-chips.
2 · Reply
Twills08
Twills08 Nov. 15 at 3:01 AM
$ITRM $PFE I don’t disagree…the next two weeks are going to be interesting…
0 · Reply
QuantInsider
QuantInsider Nov. 15 at 1:45 AM
$PFE took a hit today with a 2.8% drop The biggest move was a massive ask-side sweep in Dec 19 $25 puts showing serious demand for downside protection That's 8,475 contracts at $670,849 This kind of action usually means traders expect more downside so be careful with fresh longs until things settle Plus, Reuters dropped news after the close that Starboard bailed on their PFE stake Losing that activist pressure could dampen any near-term upside Even with a 3% bounce over the last 5 days this combo makes the setup look pretty bearish right now
1 · Reply
Find_the_Cure
Find_the_Cure Nov. 15 at 1:42 AM
$PFE TRASH
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 15 at 1:32 AM
Enter: $PFE Calls Strike Price: $26 Expiry Date: DEC 05 2025 Buy in Price: $0.29 - $0.35 Sell Price: $0.47 Profit : +61% (Turn every $1 into $1.61) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
look2theblue
look2theblue Nov. 15 at 1:31 AM
$ITRM Yep. Company (the patents really) are for sale for $15 Million (26m marketcap - 11m cash). $PFE risks losing it to anyone willing to buy the outstanding shares Monday morning. There is no poison pill in place.
1 · Reply
look2theblue
look2theblue Nov. 15 at 1:06 AM
$ITRM With $11.1 million cash on hand and a marketcap of $26. million, $PFE could purchase the outstanding shares this weekend for just $15 million dollars. That valuation imbalance most certainly makes this a takeout target over the next few days.
1 · Reply
Mukulu2025
Mukulu2025 Nov. 14 at 11:44 PM
$PFE Erratic price action tells it wants to go down. Will add more if it hits $23.90.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 11:21 PM
$PFE is currently trading at $25.06, with an RSI of 53.22 indicating neutral momentum. The price is above the 30-day moving average (MA30) of $24.88 and the 50-day moving average (MA50) of $24.79, suggesting a bullish bias in the short term. The recent 60-day high of $27.69 presents a potential resistance level, while the 60-day low of $23.58 serves as a support level. Given the current market context, a suggested entry point would be around $25.10, slightly above the last close to confirm upward momentum. A stop loss can be set at $24.70 to limit potential losses. For targets, consider $26.00 as the first target, aligning with a reasonable resistance level, and $27.00 as a second target, approaching the 60-day high. This plan leverages the current price action and technical indicators to capitalize on potential upward movement. https://privateprofiteers.com
0 · Reply
Dagrinch
Dagrinch Nov. 14 at 10:50 PM
$PFE like a movie i watched 13th warrior you cant kill the army till you kill the mother. nividia
0 · Reply
Dagrinch
Dagrinch Nov. 14 at 10:47 PM
$PFE said it’s all about rotation and it wont happen till tech dies. I dont think nividia gonna miss i actually think it will prolong the pain. Setting my buy in lower this time. 23.80 i hope i dont get my shares. If tech dies it dies with a bang i feel. I think all tech rallies into nivida earnings
0 · Reply
sister
sister Nov. 14 at 10:44 PM
$MRNA can always get cheaper . . . $NVO and $PFE too.
0 · Reply
Dagrinch
Dagrinch Nov. 14 at 10:43 PM
$PFE i escaped and if it goes back to 24.50 im gonna be trapped again. This stock hates 26 will hit it will go over for a day but always comes back home f me
0 · Reply
Sniperfyre
Sniperfyre Nov. 14 at 10:15 PM
$PFE glad I sold yesterday, this will come back down with the rest of healthcare. It needs to cool down after its run. Plus money will be piling back into tech, especially after BH just bought Google….
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Nov. 14 at 9:40 PM
$PFE 🥰
1 · Reply
up2moon
up2moon Nov. 14 at 9:35 PM
$PFE Well, at least they won't be selling anymore
2 · Reply